ArticleFrontiers in immunology2026
Efficacy and safety analysis of PD-1 inhibitors combined with chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess the efficacy and safety of integrating programmed death-1 (PD-1) inhibitors with chemoradiotherapy (CRT) in the treatment of locally advanced nasopharyngeal carcinoma (LA-NPC), explore the optimal sequencing of immunotherapy, and to compare the short-term efficacy of different combination regimens during the induction phase. Methods: We retrospectively analyzed 512 LA-NPC patients (stage III-IVA, excluding T3N0). Among these patients, 256 received PD-1 inhibitors combined with CRT, and another 256 underwent CRT alone. The two groups were matched for T stage, N stage, overall tumor stage, sex, and age. We compared outcomes including progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional failure-free survival (LRFFS), overall survival (OS), and adverse events between the two groups. Further subgroup analyses examined the 3-year PFS rates according to the timing of PD-1 inhibitor administration (induction, concurrent, and maintenance immunotherapy, induction plus concurrent immunotherapy, and induction-phase immunotherapy). We also compared the short-term efficacy of PD-1 inhibitors combined with induction chemotherapy (IC) versus IC alone, and the efficacy variations associated with antiangiogenic or anti- epidermal growth factor receptor (EGFR) therapy, different PD-1 inhibitors, and chemotherapy protocols. Results: The PD-1 inhibitor combined with CRT group showed significantly improved 3-, 4-, and 5-year rates of PFS, OS, and DMFS compared to the CRT group (3-year PFS: 90.6% vs. 82.6%, 4-year PFS: 89.3% vs. 77.3%, 5-year PFS: 89.3% vs. 76.1%; all Conclusions: Combining PD-1 inhibitors with CRT significantly improves PFS, DMFS and OS in LA-NPC patients, with a favorable safety profile. No significant differences in efficacy were found across different PD-1 inhibitors and chemotherapy regimens, suggesting flexibility in treatment selection based on clinical circumstances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.